Oral Drug Absorption in Pediatric Populations

Oral Drug Absorption: Prediction and Assessment, Second Edition

Volumn , Issue , 2016, Pages 108-126

  Edginton, Andrea N ^a   Fotaki, Nikoletta ^b  

^a UNIVERSITY OF WATERLOO   (Canada)

^b University of Bath   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85136378043     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420077346-7     Document Type: Chapter

References (106)

1. Rose K. Challenges in pediatric drug development: a pharmaceutical industry perspective. Paediatr Drugs 2009; 11(1):57-59.
2. Gazarian M. Delivering better medicines to children: need for better integration between the science, the policy, and the practice. Paediatr Drugs 2009; 11(1):41-44.
3. DiPiro J. Encyclopedia of Clinical Pharmacy. Informa Health Care, 2003.
4. Ernest TB, Elder DP, Martini LG, et al. Developing paediatric medicines: identifying the needs and recognizing the challenges. J Pharm Pharmacol 2007; 59(8):1043-1055.
5. de Zwart LL, Haenen HE, Versantvoort CH, et al. Role of biokinetics in risk assessment of drugs and chemicals in children. Regul Toxicol Pharmacol 2004; 39(3):282-309.
6. Kearns GL, Bradley JS, Jacobs RF, et al. Single dose pharmacokinetics of pleconaril in neonates. Pediatric Pharmacology Research Unit Network. Pediatr Infect Dis J 2000; 19(9):833-839.
7. EMEA. Reflection paper: Formulations of choice for the paediatric population. Available at: http://www.emea.europa.eu/pdfs/human/paediatrics/19481005en. pdf. Accessed April 15, 2009.
8. Avery GB, Randolph JG, Weaver T. Gastric acidity in the first day of life. Pediatrics 1966; 37(6):1005-1007.
9. Omari TI, Davidson GP. Multipoint measurement of intragastric pH in healthy preterm infants. Arch Dis Child Fetal Neonatal Ed 2003; 88(6):F517-F520.
10. Rodbro P, Krasilnikoff PA, Christiansen PM. Parietal cell secretory function in early childhood. Scand J Gastroenterol 1967; 2(3):209-213.
11. Huang NN, High RH. Comparison of serum levels following the administration of oral and parenteral preparations of penicillin to infants and children of various age groups. J Pediatr 1953; 42(6):657-658.
12. Al Za’abi M, Lanner A, Xiaonian X, et al. Application of routine monitoring data for determination of the population pharmacokinetics and enteral bioavailability of phenytoin in neonates and infants with seizures. Ther Drug Monit 2006; 28(6):793-799.
13. Morselli PL, Franco-Morselli R, Bossi L. Clinical pharmacokinetics in newborns and infants. Age-related differences and therapeutic implications. Clin Pharmacokinet 1980; 5(6):485-527.
14. Radde IC. Mechanisms of drug absorption and their development. In: McLeod SM, Radde IC, eds. Textbook of Pediatric Clinical Pharmacology. Littleton: PSG Publishing Co. Inc., 1985:17-43.
15. Barraclough M, Taylor CJ. Twenty-four hour ambulatory gastric and duodenal pH profiles in cystic fibrosis: effect of duodenal hyperacidity on pancreatic enzyme function and fat absorption. J Pediatr Gastroenterol Nutr 1996; 23(1):45-50.
16. Fallingborg J, Christensen LA, Ingeman-Nielsen M, et al. Measurement of gastrointestinal pH and regional transit times in normal children. J Pediatr Gastroenterol Nutr 1990; 11(2):211-214.
17. Dokumenta Geigy. Wissenschaftliche Tabellen. 7th ed. Basle, Switzerland: J.R. Geigy S.A., 1969.
18. Treier R, Steingoetter A, Weishaupt D, et al. Gastric motor function and emptying in the right decubitus and seated body position as assessed by magnetic resonance imaging. J Magn Reson Imaging 2006; 23(3):331-338.
19. Siegel M, Lebenthal E, Krantz B. Effect of caloric density on gastric emptying in premature infants. J Pediatr 1984; 104(1):118-122.
20. Besunder JB, Reed MD, Blumer JL. Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (part I). Clin Pharmacokinet 1988; 14(4):189-216.
21. Van Den Driessche M, Veereman-Wauters G. Gastric emptying in infants and children. Acta Gastroenterol Belg 2003; 66(4):274-282.
22. Bode S, Dreyer M, Greisen G. Gastric emptying and small intestinal transit time in preterm infants: a scintigraphic method. J Pediatr Gastroenterol Nutr 2004; 39(4):378-382.
23. Pozler O, Neumann D, Vorisek V, et al. Development of gastric emptying in premature infants. Use of the (13)C-octanoic acid breath test. Nutrition 2003, 19(7-8):593-596.
24. Vivatvakin B, Buachum V. Effect of carob bean on gastric emptying time in Thai infants. Asia Pac J Clin Nutr 2003; 12(2):193-197.
25. Garzi A, Messina M, Frati F, et al. An extensively hydrolysed cow’s milk formula improves clinical symptoms of gastroesophageal reflux and reduces the gastric emptying time in infants. Allergol Immunopathol (Madr) 2002; 30(1):36-41.
26. Shaaban SY, Nassar MF, Sawaby AS, et al. Ultrasonographic gastric emptying in protein energy malnutrition: effect of type of meal and nutritional recovery. Eur J Clin Nutr 2004; 58(6):972-978.
27. Maes BD, Ghoos YF, Geypens BJ, et al. Relation between gastric emptying rate and energy intake in children compared with adults. Gut 1995; 36(2):183-188.
28. Bouras EP, Burton DD, Camilleri M, et al. Effect of cyclooxygenase-2 inhibitors on gastric emptying and small intestinal transit in humans. Neurogastroenterol Motil 2004; 16(6):729-735.
29. Singh SJ, Gibbons NJ, Blackshaw PE, et al. Gastric emptying of solids in normal children-a preliminary report. J Pediatr Surg 2006; 41(2):413-417.
30. Ofori-Kwakye K, Fell JT, Sharma HL, et al. Gamma scintigraphic evaluation of filmcoated tablets intended for colonic or biphasic release. Int J Pharm 2004; 270(1-2):307-313.
31. Levy G, Khanna NN, Soda DM, et al. Pharmacokinetics of acetaminophen in the human neonate: formation of acetaminophen glucuronide and sulfate in relation to plasma bilirubin concentration and D-glucaric acid excretion. Pediatrics 1975; 55(6):818-825.
32. Anderson BJ, Woollard GA, Holford NH. A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. Br J Clin Pharmacol 2000; 50(2):125-134.
33. Hassan M, Ljungman P, Bolme P, et al. Busulfan bioavailability. Blood 1994; 84(7):2144-2150.
34. Heimann G. Enteral absorption and bioavailability in children in relation to age. Eur J Clin Pharmacol 1980; 18(1):43-50.
35. Silverio J, Poole JW. Serum concentrations of ampicillin in newborn infants after oral administration. Pediatrics 1973; 51(3):578-580.
36. Jusko WJ, Khanna N, Levy G, et al. Riboflavin absorption and excretion in the neonate. Pediatrics 1970; 45(6):945-949.
37. Toublanc N, Sargentini-Maier ML, Lacroix B, et al. Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy:dosing recommendations. Clin Pharmacokinet 2008; 47(5):333-341.
38. Milsap RL, Jusko WJ. Pharmacokinetics in the infant. Environ Health Perspect 1994; 102(suppl 11):107-110.
39. Bartelink IH, Rademaker CM, Schobben AF, et al. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 2006; 45(11):1077-1097.
40. Vreugdenhil G, Sinaasappel M, Bouquet J. A comparative study of the mouth to caecum transit time in children and adults using a weight adapted lactulose dose. Acta Paediatr Scand 1986; 75(3):483-488.
41. Hoekstra JH. Fructose breath hydrogen tests in infants with chronic non-specific diarrhoea. Eur J Pediatr 1995; 154(5):362-364.
42. Khin M, Bolin TD, Tin O, et al. Investigation of small-intestinal transit time in normal and malnourished children. J Gastroenterol 1999; 34(6):675-679.
43. Van Den Driessche M, Van MN, Geypens B, et al. Lactose-[13C]ureide breath test: a new, noninvasive technique to determine orocecal transit time in children. J Pediatr Gastroenterol Nutr 2000; 31(4):433-438.
44. Soares AC, Lederman HM, Fagundes-Neto U, et al. Breath hydrogen test after a bean meal demonstrates delayed oro-cecal transit time in children with chronic constipation. J Pediatr Gastroenterol Nutr 2005; 41(2):221-224.
45. Graff J, Brinch K, Madsen JL. Gastrointestinal mean transit times in young and middle-aged healthy subjects. Clin Physiol 2001; 21(2):253-259.
46. Weaver LT, Laker MF, Nelson R. Intestinal permeability in the newborn. Arch Dis Child 1984; 59(3):236-241.
47. Rouwet EV, Heineman E, Buurman WA, et al. Intestinal permeability and carriermediated monosaccharide absorption in preterm neonates during the early postnatal period. Pediatr Res 2002; 51(1):64-70.
48. Ford RP, Menzies IS, Phillips AD, et al. Intestinal sugar permeability: relationship to diarrhoeal disease and small bowel morphology. J Pediatr Gastroenterol Nutr 1985; 4(4):568-574.
49. Johnston JD, Harvey CJ, Menzies IS, et al. Gastrointestinal permeability and absorptive capacity in sepsis. Crit Care Med 1996; 24(7):1144-1149.
50. Helander HF. Quantitative morphological methods in intestinal research. Scand J Gastroenterol Suppl 1985; 112:1-5.
51. McClean P, Dodge JA, Nunn S, et al. Surface features of small-intestinal mucosa in childhood diarrheal disorders. J Pediatr Gastroenterol Nutr 1996; 23(5):538-546.
52. Stenling R, Fredrikzon B, Nyhlin H, et al. Surface ultrastructure of the small intestine mucosa in healthy children and adults: a scanning electron microscopic study with some methodological aspects. Ultrastruct Pathol 1984; 6(2-3):131-140.
53. Henderson TR, Hamosh M, Armand M, et al. Gastric proteolysis in preterm infants fed mother’s milk or formula. Adv Exp Med Biol 2001; 501:403-408.
54. RIVM. Interspeciesinfo. National Institute for Public Health and the Environment Available at: http://www.rivm.nl/interspeciesinfo/intra/human/stomach/db_human_ stomach.jsp. Accessed April 17, 2009.
55. Bajaj-Elliott M, Sanderson IR. Gene Expression, Part II: Physiology and Pathophysiology. In: Walker WA, Watkins JB, Duggan C, eds. Nutrition in Paediatrics:Basic Science and Clinical Applications. 3rd ed. Ontario: BC Decker Inc., 2003.
56. Murphy GM, Signer E. Bile acid metabolism in infants and children. Gut 1974; 15(2):151-163.
57. Boehm G, Bierbach U, DelSanto A, et al. Activities of trypsin and lipase in duodenal aspirates of healthy preterm infants: effects of gestational and postnatal age. Biol Neonate 1995; 67(4):248-253.
58. Hamosh M. Lipid metabolism in premature infants. Biol Neonate 1987; 52(suppl 1):50-64.
59. RIVM. Interspeciesinfo. National Institute for Public Health and the Environment Available at: http://www.rivm.nl/interspeciesinfo/intra/human/int_small/db_ human_small_intestine.jsp. Accessed May 17, 2009.
60. Doeel RG, Kretchmer N. Studies of small intestine during development. I. Distribution and activity of beta-galactosidase. Biochim Biophys Acta 1962, 62: 353-362.
61. Kretchmer N. Lactose and lactase-a historical perspective. Gastroenterology 1971; 61(6):805-813.
62. Reddy BS, Wostmann BS. Intestinal disaccharidase activities in the growing germfree and conventional rats. Arch Biochem Biophys 1966; 113(3):609-616.
63. Robberecht P, Schodt-Lanckman M, Camus J, et al. Rat pancreatic hydrolases from birth to weaning and dietary adaptation after weaning. Am J Physiol 1971; 221(1):376-381.
64. Stahlberg MR, Hietanen E, Maki M. Mucosal biotransformation rates in the small intestine of children. Gut 1988; 29(8):1058-1063.
65. Suchy FJ, Sokal RJ, Balistreri WF. Liver Disease in Children. 3rd ed. Cambridge:University Press, 2007.
66. Boehm G, Braun W, Moro G, et al. Bile acid concentrations in serum and duodenal aspirates of healthy preterm infants: effects of gestational and postnatal age. Biol Neonate 1997; 71(4):207-214.
67. Watkins JB. Bile salts: normal metabolism and pathophysiology. In: Anderson CM, Burke V, Gracey M, eds. Paediatric Gastroeneterology. 2nd ed. New York: Blackwell Scientific Publications, 1987.
68. Tasdemir HA, Cetinkaya MC, Polat C, et al. Gallbladder motility in children with Down syndrome. J Pediatr Gastroenterol Nutr 2004; 39(2):187-191.
69. Bolukbas FF, Bolukbas C, Horoz M, et al. Risk factors associated with gallstone and biliary sludge formation during pregnancy. J Gastroenterol Hepatol 2006; 21(7):1150-1153.
70. Suchy FJ, Balistreri WF, Heubi JE, et al. Physiologic cholestasis: elevation of the primary serum bile acid concentrations in normal infants. Gastroenterology 1981; 80(5 pt 1):1037-1041.
71. Poley JR, Dower JC, Owen CA Jr, et al. Bile acids in infants and children. J Lab Clin Med 1964; 63:838-846.
72. Henning SJ. Postnatal development: coordination of feeding, digestion, and metabolism. Am J Physiol 1981; 241(3):G199-G214.
73. Johnson TN, Thomson M. Intestinal metabolism and transport of drugs in children:the effects of age and disease. J Pediatr Gastroenterol Nutr 2008; 47(1):3-10.
74. Johnson TN, Tanner MS, Taylor CJ, et al. Enterocytic CYP3A4 in a paediatric population:developmental changes and the effect of coeliac disease and cystic fibrosis. Br J Clin Pharmacol 2001; 51(5):451-460.
75. Miki Y, Suzuki T, Tazawa C, et al. Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues. Mol Cell Endocrinol 2005; 231(1-2):75-85.
76. Fakhoury M, Litalien C, Medard Y, et al. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab Dispos 2005; 33(11):1603-1607.
77. Daood M, Tsai C, Hdab-Barmada M, et al. ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS. Neuropediatrics 2008; 39(4):211-218.
78. Hoppu K, Koskimies O, Holmberg C, et al. Evidence for pre-hepatic metabolism of oral cyclosporine in children. Br J Clin Pharmacol 1991; 32(4):477-481.
79. Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinet 2002; 41(12):959-998.
80. Hines RN. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 2008; 118(2):250-267.
81. de Wildt SN, Kearns GL, Hop WC, et al. Pharmacokinetics and metabolism of oral midazolam in preterm infants. Br J Clin Pharmacol 2002; 53(4):390-392.
82. Boucher FD, Modlin JF, Weller S, et al. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr 1993; 122(1):137-144.
83. Tod M, Lokiec F, Bidault R, et al. Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. Antimicrob Agents Chemother 2001; 45(1):150-157.
84. de Zwart L, Scholten M, Monbaliu JG, et al. The ontogeny of drug metabolizing enzymes and transporters in the rat. Reprod Toxicol 2008; 26(3-4):220-230.
85. Schuetz EG, Furuya KN, Schuetz JD. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 1995; 275(2):1011-1018.
86. Linday L, Dobkin JF, Wang TC, et al. Digoxin inactivation by the gut flora in infancy and childhood. Pediatrics 1987; 79(4):544-548.
87. Schiltmeyer B, Klingebiel T, Schwab M, et al. Population pharmacokinetics of oral busulfan in children. Cancer Chemother Pharmacol 2003; 52(3):209-216.
88. Kearns GL, Reed MD, Jacobs RF, et al. Single-dose pharmacokinetics of ceftibuten (SCH 39720) in infants and children. Antimicrob Agents Chemother 1991; 35(10):2078-2084.
89. Chien S, Wells TG, Blumer JL, et al. Levofloxacin pharmacokinetics in children. J Clin Pharmacol 2005; 45(2):153-160.
90. Sokal EM, Kelly D, Wirth S, et al. The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection. J Clin Pharmacol 2008; 48(4):512-517.
91. Kearns GL, Blumer J, Schexnayder S, et al. Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents. J Clin Pharmacol 2008; 48(11):1356-1365.
92. Kearns GL, Robinson PK, Wilson JT, et al. Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. Clin Pharmacol Ther 2003; 74(4):312-325.
93. Blumer J, Batisky DL, Wells T, et al. Pharmacokinetics of valsartan in pediatric and adolescent subjects with hypertension. J Clin Pharmacol 2009; 49(2):235-241.
94. Albani M, Wernicke I. Oral phenytoin in infancy: dose requirement, absorption, and elimination. Pediatr Pharmacol (New York) 1983; 3(3-4):229-236.
95. Johnson DA, Roach AC, Carlsson AS, et al. Stability of esomeprazole capsule contents after in vitro suspension in common soft foods and beverages. Pharmacotherapy 2003; 23(6):731-734.
96. Carrier MN, Garinot O, Vitzling C. Stability and compatibility of tegaserod from crushed tablets mixed in beverages and foods. Am J Health Syst Pharm 2004; 61(11):1135-1142.
97. Yamreudeewong W, Danthi SN, Hill RA, et al. Stability of ondansetron hydrochloride injection in various beverages. Am J Health Syst Pharm 1995; 52(18):2011-2014.
98. Nahata MC. Stability of labetalol hydrochloride in distilled water, simple syrup, and three fruit juices. DICP 1991; 25(5):465-469.
99. Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Expert Opin Drug Deliv 2007; 4(1):37-45.
100. Standing JF, Tuleu C. Paediatric formulations-getting to the heart of the problem. Int J Pharm 2005; 300(1-2):56-66.
101. Strickley RG, Iwata Q, Wu S, et al. Pediatric drugs-a review of commercially available oral formulations. J Pharm Sci 2008; 97(5):1731-1774.
102. Cram A, Breitkreutz J, Sset-Brethes S, et al. Challenges of developing palatable oral paediatric formulations. Int J Pharm 2009; 365(1-2):1-3.
103. Kayitare E, Vervaet C, Ntawukulilyayo JD, et al. Development of fixed dose combination tablets containing zidovudine and lamivudine for paediatric applications. Int J Pharm 2009; 370(1-2):41-46.
104. Kyngas HA, Skaar-Chandler CA, Duffy ME. The development of an instrument to measure the compliance of adolescents with a chronic disease. J Adv Nurs 2000; 32(6):1499-1506.
105. Pedersen S, Steffensen G. Absorption characteristics of once-a-day slow-release theophylline preparation in children with asthma. J Pediatr 1987; 110(6):953-959.
106. Rogers RJ, Kalisker A, Wiener MB, et al. Inconsistent absorption from a sustainedrelease theophylline preparation during continuous therapy in asthmatic children. J Pediatr 1985; 106(3):496-501.